Zhou Zi-Yi, Wang Lin, Wang Yu-Sheng, Dou Guo-Rui
Department of Ophthalmology, Xijing Hospital, Eye Institute of Chinese PLA, Fourth Military Medical University, Xi'an, China.
Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Front Cell Dev Biol. 2021 Mar 11;9:628317. doi: 10.3389/fcell.2021.628317. eCollection 2021.
The current treatment for ocular pathological angiogenesis mainly focuses on anti-VEGF signals. This treatment has been confirmed as effective despite the unfavorable side effects and unsatisfactory efficiency. Recently, endothelial cell metabolism, especially glycolysis, has been attracting attention as a potential treatment by an increasing number of researchers. Emerging evidence has shown that regulation of endothelial glycolysis can influence vessel sprouting. This new evidence has raised the potential for novel treatment targets that have been overlooked for a long time. In this review, we discuss the process of endothelial glycolysis as a promising target and consider regulation of the enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase as treatment for ocular pathological angiogenesis.
目前针对眼部病理性血管生成的治疗主要集中在抗血管内皮生长因子(VEGF)信号方面。尽管存在不良副作用且效率不尽人意,但这种治疗方法已被证实是有效的。最近,内皮细胞代谢,尤其是糖酵解,正作为一种潜在的治疗方法受到越来越多研究人员的关注。新出现的证据表明,调节内皮细胞糖酵解可以影响血管生成。这一新证据凸显了长期以来被忽视的新型治疗靶点的潜力。在这篇综述中,我们将探讨内皮细胞糖酵解作为一个有前景的靶点的过程,并考虑将6-磷酸果糖-2-激酶/果糖-2,6-二磷酸酶的调节作为眼部病理性血管生成的治疗方法。